Research ArticleArticle
A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients
Heidi J Einolf, Jocelyn Zhou, Christina Won, Lai Wang and Sam Rebello
Drug Metabolism and Disposition January 25, 2017, dmd.116.073585; DOI: https://doi.org/10.1124/dmd.116.073585
Heidi J Einolf
Novartis Pharmaceuticals Corporation
Jocelyn Zhou
Novartis Pharmaceuticals Corporation
Christina Won
Novartis Pharmaceuticals Corporation
Lai Wang
Novartis Pharmaceuticals Corporation
Sam Rebello
Novartis Pharmaceuticals Corporation
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients
Heidi J Einolf, Jocelyn Zhou, Christina Won, Lai Wang and Sam Rebello
Drug Metabolism and Disposition January 25, 2017, dmd.116.073585; DOI: https://doi.org/10.1124/dmd.116.073585
Research ArticleArticle
A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients
Heidi J Einolf, Jocelyn Zhou, Christina Won, Lai Wang and Sam Rebello
Drug Metabolism and Disposition January 25, 2017, dmd.116.073585; DOI: https://doi.org/10.1124/dmd.116.073585
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement